SLC2A1 and breast carcinoma: In summary, evidence suggests that GLUT1, HK2, LDHA, MCT1, PKM2 and PFK1 could become potential biomarkers, either diagnostic or prognostic, in breast cancer, depending on the molecular subtypes and treatment involved.